Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Perkins

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
International Journal of Pharmaceutics|September 16, 1999
Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulationsA C Perkins, C G Wilson, M Frier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595O D Hughes, M C Bishop, A C Perkins, et al.
International Journal of Pharmaceutics|June 28, 2001
The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of waterA C Perkins, C G Wilson, M Frier, et al.
European Journal of Nuclear Medicine|January 1, 1990
Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragmentsA Chetanneau, R P Baum, P A Lehur, et al.
British Journal of Cancer|December 16, 2004
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugateC F Qu, Y Li, Y J Song, et al.
Alimentary Pharmacology & Therapeutics|November 18, 2003
Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humansN S Coleman, L Marciani, E Blackshaw, et al.
Physics in Medicine and Biology|January 17, 2015
Measurement of gastric meal and secretion volumes using magnetic resonance imagingC L Hoad, H Parker, N Hudders, et al.
The British Journal of Surgery|December 1, 1986
In vitro binding and in vivo localization in colorectal cancer of a high affinity monoclonal antibody to carcinoembryonic antigenN C Armitage, A C Perkins, L G Durrant, et al.
Alimentary Pharmacology & Therapeutics|July 15, 2010
Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imagingL Marciani, J Wright, S Foley, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
British Journal of Obstetrics and Gynaecology|July 30, 1999
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinomaQ Davies, A C Perkins, J C Roos, et al.
International Journal of Pharmaceutics|September 16, 1999
Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulationsA C Perkins, C G Wilson, M Frier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595O D Hughes, M C Bishop, A C Perkins, et al.
International Journal of Pharmaceutics|June 28, 2001
The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of waterA C Perkins, C G Wilson, M Frier, et al.
European Journal of Nuclear Medicine|January 1, 1990
Multi-centre immunoscintigraphic study using indium-111-labelled CEA-specific and/or 19-9 monoclonal antibody F(ab')2 fragmentsA Chetanneau, R P Baum, P A Lehur, et al.
British Journal of Cancer|December 16, 2004
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugateC F Qu, Y Li, Y J Song, et al.
Alimentary Pharmacology & Therapeutics|November 18, 2003
Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humansN S Coleman, L Marciani, E Blackshaw, et al.
Physics in Medicine and Biology|January 17, 2015
Measurement of gastric meal and secretion volumes using magnetic resonance imagingC L Hoad, H Parker, N Hudders, et al.
The British Journal of Surgery|December 1, 1986
In vitro binding and in vivo localization in colorectal cancer of a high affinity monoclonal antibody to carcinoembryonic antigenN C Armitage, A C Perkins, L G Durrant, et al.
Alimentary Pharmacology & Therapeutics|July 15, 2010
Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imagingL Marciani, J Wright, S Foley, et al.
Pageof 18